Skip to content

Nusinersen sodium

Spinraza (nusinersen sodium) is an oligonucleotide pharmaceutical. Nusinersen sodium was first approved as Spinraza on 2017-05-30. It has been approved in Europe to treat spinal muscular atrophy. Spinraza's patents are valid until 2035-09-11 (FDA).
Trade Name Spinraza
Common Name Nusinersen sodium
Indication spinal muscular atrophy
Drug Class Antisense oligonucleotides
Nusinersen sodium
Get full access now